Fjarde AP Fonden Fourth Swedish National Pension Fund cut its stake in shares of Celgene Corporation (NASDAQ:CELG) by 6.7% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 155,171 shares of the biopharmaceutical company’s stock after selling 11,094 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Celgene Corporation were worth $19,308,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of CELG. Diversified Trust Co boosted its position in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 9 shares during the last quarter. Cadence Bank NA raised its position in shares of Celgene Corporation by 0.6% in the first quarter. Cadence Bank NA now owns 7,496 shares of the biopharmaceutical company’s stock valued at $933,000 after buying an additional 45 shares during the last quarter. Washington Trust Bank raised its position in shares of Celgene Corporation by 1.3% in the first quarter. Washington Trust Bank now owns 3,613 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 46 shares during the last quarter. Beach Investment Management LLC. raised its position in shares of Celgene Corporation by 0.8% in the first quarter. Beach Investment Management LLC. now owns 6,200 shares of the biopharmaceutical company’s stock valued at $771,000 after buying an additional 50 shares during the last quarter. Finally, 1ST Source Bank raised its position in shares of Celgene Corporation by 0.5% in the first quarter. 1ST Source Bank now owns 12,173 shares of the biopharmaceutical company’s stock valued at $1,515,000 after buying an additional 65 shares during the last quarter. 78.34% of the stock is owned by institutional investors and hedge funds.

Celgene Corporation (NASDAQ CELG) traded down 0.08% during trading on Friday, hitting $129.95. 740,822 shares of the stock were exchanged. The firm has a 50-day moving average of $133.46 and a 200-day moving average of $125.29. The stock has a market capitalization of $101.67 billion, a price-to-earnings ratio of 40.24 and a beta of 1.89. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the previous year, the firm earned $1.44 earnings per share. Celgene Corporation’s revenue was up 18.7% on a year-over-year basis. Equities research analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/25/fjarde-ap-fonden-fourth-swedish-national-pension-fund-has-19-31-million-position-in-celgene-corporation-celg.html.

Several research analysts have recently commented on the company. Jefferies Group LLC set a $154.00 price target on Celgene Corporation and gave the stock a “buy” rating in a research report on Saturday, May 13th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research note on Wednesday, August 9th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective on the stock in a research note on Wednesday, August 16th. Cantor Fitzgerald restated a “buy” rating on shares of Celgene Corporation in a research note on Tuesday. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $150.00 price target on shares of Celgene Corporation in a research note on Friday, July 14th. One research analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the stock. Celgene Corporation currently has a consensus rating of “Buy” and an average target price of $147.44.

In other news, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50. The disclosure for this sale can be found here. Insiders have sold 253,761 shares of company stock valued at $33,792,445 in the last three months. 0.95% of the stock is owned by insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.